+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

BCG Vaccine Market by Demographics [Pediatrics] - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4403151
  • Report
  • September 2017
  • Region: Global
  • 150 pages
  • Allied Analytics LLP
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The global BCG vaccine market is estimated to reach $28,051 thousand by 2023, growing at a CAGR of 4.6% from 2017 to 2023, from $20,366 thousand in 2016. Bacillus Calmette-Guérin (BCG) vaccine is the only vaccine available for prevention of human forms of tuberculosis (TB). This vaccine is generally administered to children at birth in countries with high incidence of TB. In regions with low level of TB, only children at high risk are typically immunized, whereas adults are generally not immunized. However, adults (up to the age of 35) who are frequently exposed to drug-resistant TB may also be given BCG vaccine.

The global BCG vaccine market is driven by increase in prevalence of tuberculosis and rise in technological advancements in vaccine research. Moreover, the increase in government initiatives and focus on immunization programs globally boost the market growth. However, side effects of BCG vaccine and a global shortage of BCG vaccine restrain this growth. Untapped market potential in developing regions is expected to present numerous opportunities for market development.

The global BCG vaccine market is segmented on the basis of demographics and country. Based on demographics, it is bifurcated into pediatrics (0-18 years), and adults (19-35 years. Based on country, it is analyzed across India, China, Bangladesh, Pakistan, Indonesia, Japan, Brazil, Mexico, South Africa, Kenya, Thailand, Argentina, Colombia, Chile, Singapore, and rest of the world.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global BCG vaccine market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

BY DEMOGRAPHICS

Pediatrics (0-18 Years)
Adults (19-35 Years)

By Country

India
China
Bangladesh
Pakistan
Indonesia
Japan
Brazil
Mexico
South Africa
Kenya
Thailand
Argentina
Colombia
Chile
Singapore
Rest of the world

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Merck & Co., Inc.
Sanofi Pasteur
Japan BCG Laboratory
China National Biotec Group (a subsidiary of China National Pharmaceutical Group Corporation)
Serum Institute of India Pvt. Ltd.
InterVax Ltd.
GreenSignal Bio Pharma Limited (GSBPL)
Statens Serum Institut
Note: Product cover images may vary from those shown
2 of 3
CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.1.1. Secondary research
1.1.2. Primary research
1.1.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Competitive intelligence of companies and their strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS

3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.4.4. Impact analysis

3.5. CLINICAL TRIALS

CHAPTER 4 GLOBAL BCG VACCINE MARKET, BY DEMOGRAPHICS

4.1. OVERVIEW

4.1.1. Key market trends
4.1.2. Growth factors and opportunities
4.1.3. Market size and forecast

4.2. PEDIATRICS (AGE 0-18 YEARS)

4.2.1. Market size and forecast

4.3. ADULTS (AGE 19-35 YEARS)

4.3.1. Market size and forecast

CHAPTER 5 BCG VACCINE MARKET, BY COUNTRY

5.1. OVERVIEW

5.1.1. Key market trends
5.1.2. Growth factors and opportunities
5.1.3. Market size and forecast

5.2. INDIA

5.2.1. Market size and forecast

5.3. CHINA

5.3.1. Market size and forecast

5.4. BANGLADESH

5.4.1. Market size and forecast

5.5. PAKISTAN

5.5.1. Market size and forecast

5.6. INDONESIA

5.6.1. Market size and forecast

5.7. JAPAN

5.7.1. Market size and forecast

5.8. BRAZIL

5.8.1. Market size and forecast

5.9. MEXICO

5.9.1. Market size and forecast

5.10. SOUTH AFRICA

5.10.1. Market size and forecast

5.11. KENYA

5.11.1. Market size and forecast

5.12. THAILAND

5.12.1. Market size and forecast

5.13. ARGENTINA

5.13.1. Market size and forecast

5.14. COLOMBIA

5.14.1. Market size and forecast

5.15. CHILE

5.15.1. Market size and forecast

5.16. SINGAPORE

5.16.1. Market size and forecast

5.17. REST OF THE WORLD

5.17.1. Market size and forecast

CHAPTER 6 COMPANY PROFILES

6.1. CHINA NATIONAL BIOTEC GROUP (A SUBSIDIARY OF CHINA NATIONAL PHARMACEUTICAL GROUP CORPORATION)

6.1.1. Company overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves and developments

6.2. GREENSIGNAL BIO PHARMA LIMITED

6.2.1. Company overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves and developments

6.3. INTERVAX LTD.

6.3.1. Company overview
6.3.2. Operating business segments
6.3.3. Business performance
6.3.4. Key strategic moves and developments

6.4. JAPAN BCG LABORATORY

6.4.1. Company overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves and developments

6.5. MERCK & CO., INC.

6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves and developments

6.6. SANOFI PASTEUR

6.6.1. Company overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key strategic moves and developments

6.7. SERUM INSTITUTE OF INDIA PVT. LTD.

6.7.1. Company overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key strategic moves and developments

6.8. STATENS SERUM INSTITUT

6.8.1. Company overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll